Directrice commerciale at BioReBone Project - Heerhugowaard, Noord-Holland, Netherlands
Annually, > 2 million surgical procedures are performed worldwide to repair bone defects in the jawbone or skeletal bone structures. The surgical procedure replaces the missing bone with either material derived from the patient himself (autografts), or from other donors, human cadavers or bone banks (allografts) or from other species (xenografts). Despite their extensive use, the bone grafts have limited availability and are associated with serious side effects. As such, there is an urgent medical need for alternative bone-regenerative products. Recently, Dr. Liu of the Academic Centre for Dentistry Amsterdam (ACTA) and YEKIMED (Switzerland) have developed a unique technology to produce a novel bone substitute with local, limited and time-controlled release mechanism for (bio)active molecules and compounds.